2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow pegilodecakin: new trials by email Literature Review of pegilodecakin trials Research Report on pegilodecakin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Pegilodecakin, Nivolumab - Non Small Cell Lung Cancer | Phase 2 | Terminated | Eli Lilly and Company | 52 | 2018-03-22 | 2020-09-11 |
| Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer Pegilodecakin, Pembrolizumab - Non Small Cell Lung Cancer | Phase 2 | Terminated | Eli Lilly and Company | 101 | 2018-03-19 | 2021-01-20 |
Carcinoma, Non-Small-Cell Lung (2)
United States (2)